等待開盤 09-23 09:00:00
0.000
0.00%
IO Biotech's senior management will present at Morgan Stanley's Global Healthcare Conference on September 9 and H.C. Wainwright's Global Investment Conference on September 10. The company's lead candidate, Cylembio, is in pivotal Phase 3 and two Phase 2 trials for advanced melanoma and solid tumors, with results expected in Q3 2025. IO Biotech is a clinical-stage biopharma company developing immune-modulatory cancer vaccines.
09-04 12:05